There are limited treatment options available for chronic renal disorder (CKD), and patients often still reach renal failure or premature death / The phase III clinical trial study FIND-CKD will investigate the effect of finerenone on kidney and cardiovascular outcomes…
In an updated analysis on the adult subset of non-central systema nervosum (CNS) / TRK fusion cancer patients from three larotrectinib clinical trials, a high overall response rate (ORR) of 67% with a median duration of response (mDoR) of 49.3…
Andes has developed novel seed treatment technology that allows crops to thrive without synthetic fertilizers / Funds will aid the development of revolutionary nature-based carbon capture technology Leaps by Bayer, the impact investment arm of Bayer AG, today announced that…
Updated analyses for Vitrakvi™ (larotrectinib) reaffirm sustained clinical benefits for patients with TRK fusion cancer / Breadth of prostatic adenocarcinoma portfolio on display, including presentations for Nubeqa™ (darolutamide) in non-metastatic castration-resistant prostatic adenocarcinoma (nmCRPC), and Xofigo™ (radium-223 dichloride) in metastatic…
Significant improvement in 24-hour cough counts over placebo after 12 weeks of treatment and with a positive safety and tolerability profile / Results from PAGANINI Phase IIb dose-finding study presented at the virtual European Respiratory Society (ERS) International Congress 2021…
Recommendation supported Data From Phase 3 KEYNOTE-355 Trial Merck, referred to as MSD outside the us and Canada, today announced the Committee for Medicinal Products for Human Use (CHMP) of the ecu Medicines Agency (EMA) has recommended approval of KEYTRUDA,…
Study Now Enrolling Participants Who sleep in an equivalent Household as Someone With Symptomatic, Laboratory-Confirmed COVID-19 Merck ,known as MSD outside the us and Canada, and Ridgeback Biotherapeutics announced today the initiation of the Phase 3 MOVe-AHEAD clinical test to…
New data show pre-symptomatic babies with spinal muscular atrophy (SMA) treated with Evrysdi maintained the power to swallowEvrysdi has demonstrated consistent clinically meaningful efficacy in adults, children, and babies two months and older and is now approved in 58 countries…
Acute respiratory infections are one of the leading causes of death and disability globally, presenting substantial health challenges especially for infants, the elderly and the immunocompromised.1-3 Three new molecular diagnostic test panels for influenza and other common respiratory illnesses can…
Roche today presented new data from the phase III clinical trial IMpower010 study at the ecu Society for Medical Oncology (ESMO) Congress 2021 Presidential Symposium, reinforcing the many disease-free survival (DFS) benefit offered by Tecentriq® (atezolizumab) for people with Stage…
The U.S. Food and Drug Administration today approved Byooviz (ranibizumab-nuna) because the first biosimilar to Lucentis (ranibizumab injection) for the treatment of several eye diseases and conditions, including neovascular (wet) age-related degeneration (nAMD), a number one explanation for vision loss…
The following quote is attributed to Acting FDA Commissioner Janet Woodcock, M.D “The opioid crisis continues to be a national public health emergency with devastating and far-reaching consequences extending into nearly every community. A key component of the FDA’s multipronged…